期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型口服抗凝药物临床研究进展 被引量：7

原文传递
导出
摘要 抗凝药物是预防血栓栓塞性疾病的重要药物。血栓栓塞性疾病可分为动脉性血栓栓塞疾病和静脉性血栓栓塞症（VTE）两大类，前者血栓以血小板聚集为主，含少量纤维蛋白，包括急性冠状动脉综合征（ACS）、缺血性卒中、体循环血栓栓塞，以抗血小板治疗为主，辅以抗凝治疗；而后者血栓由纤维蛋白和红细胞组成，包括深静脉血栓形成（DVT）、肺栓塞（PE）和心房颤动（房颤）卒中（房颤时血栓多发生在左心耳，为静脉样血栓），以抗凝治疗为主。华法林是目前临床最常用的口服抗凝药物，疗效确切，但其临床使用现状不理想，
作者 高润霖
机构地区 [
出处 《中华医学杂志》 CAS CSCD 北大核心 2013年第31期2523-2526,共4页 National Medical Journal of China
关键词 口服抗凝药物 临床研究 血栓栓塞性疾病 急性冠状动脉综合征 深静脉血栓形成 缺血性卒中 血栓栓塞疾病 抗血小板治疗
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献31

  • 1Weitz JI,Hirsh J.New anticoagulant drugs.Chest,2001,119:95S-107S.
  • 2Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med,2009,361:1139-1151.
  • 3Uchino K,Hemandez AV.Dabigatran association with higher risk of acute coronary events:meta-analysis of noninferiority randomized controlled trials.Arch Intern Med,2012,172:397-402.
  • 4Legrand M,Mateo J,Aribaud A,et al.The use of dabigatran in elderly patients.Arch Intern Med,2011,171:1285-1286.
  • 5Jacobs JM,Stessman J.New anticoagulant drugs among elderly patients is caution necessary?:Comment on " The use of dabigatran in elderly patients".Arch Intern Med,2011,171:1287-1288.
  • 6Mueck W,Becka M,Kubitza D,et al.Population model of the pharmacokinetics and pharmacodynanics of rivaroxaban--an oral,direct factor xa inhibitor--in healthy subjects.Int J Clin Pharmacol Ther,2007,45:335-344.
  • 7Kubitza D,Becka M,Zuehlsdorf M,et al.Effect of food,an antacid,and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban),an oral,direct factor X a inhibitor,in healthy subjects.J Clin Pharmacol,2006,46:549-558.
  • 8Connolly SJ,Eikelboom J,Joyner C,et al.Apixaban in patients with atrial fibrillation.N Engl J Med,2011,364:806-817.
  • 9Granger CB,Alexander JH,McMurray JJ,et al.Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med,2011,365:981-992.
  • 10Oldgren J,Budaj A,Granger CB,et al.Dabigatran vs.placebo in patients with acute coronary syndromes on dual antiplatelet therapy:a randomized,double-blind,phase Ⅱ trial.Eur Heart J,2011,32:2781-2789.

同被引文献85

  • 1Gordon T, Kannel WB. Predisposition to atherosclerosis in the head, heart and legs. The Framingham Study[J]. JAMA, 1972, 221 (7) : 661 -667.
  • 2Eliasson A, Bergqvist D, Bjorck M, et al. Prevalence and risk of venous thromboembolism in patients with verified arterial thrombo- sis: a population study based on 23 796 consecutive autopsies[ J ]. J Thromb Haemost, 2006, 4(9) : 1897 -1902.
  • 3Blann AD, Lip GY. "Virchow's triad revisited: the importance of soluble coagulation factors, the endothelium , and platelets" [ J ]. Thromb Res, 2001, 101(4) : 321 -327.
  • 4Lowe GD. Common risk factors for both arterial and venous throm- bosis[J]. Br J Haematol, 2008, 140(5) : 488 -495.
  • 5Falck - Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients[ J]. Chest, 2012, 141 (s2) : e278S - e325S.
  • 6Saposnik G, Barinagarrementeria F, Brown A D, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healtheare professionals from the American Heart Association/A- merican stroke Association [ J ]. Stroke, 2011, 42 (4) : 1158 - 1192.
  • 7Lee AY. Epidemiology and management of venous thromboembo- lism in patients with cancer[J]. Thromh Res, 2003, 110(4) : 167 - 172.
  • 8Thaehil J, Toh CH. Current concepts in the management of dis- seminated intravascular coagulation[ J]. Thromb Res, 2012, 129(S1):S54-S59.
  • 9Esmon CT. Crosstalk between inflammation and thrombosis [ J ]. Maturitas, 2004, 47(4) : 305 -314.
  • 10Mielicki WP. Biochemistry of cancer procoagulant[ J]. Haemo- stasis, 2001, 31 ( s1 ) : 8 - 10.

引证文献7

二级引证文献29

中华医学杂志
2013年 第31期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部